Patents by Inventor Johanna Nystedt
Johanna Nystedt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10000734Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: May 23, 2016Date of Patent: June 19, 2018Assignee: GLYKOS FINLAND OYInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20160333309Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: May 23, 2016Publication date: November 17, 2016Applicant: Glykos Finland OyInventors: Jarmo LAINE, Taina JAATINEN, Heidi ANDERSON, Johanna NYSTEDT, Sari TIITINEN, Anita LAITINEN, Ulla IMPOLA, Tero Satomaa, Jari NATUNEN, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20160215256Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: December 29, 2015Publication date: July 28, 2016Inventors: Johanna Nystedt, Heidi Anderson, Leena Valmu, Jari Natunen, Tero Satomaa
-
Patent number: 9382512Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: January 17, 2012Date of Patent: July 5, 2016Assignee: GLYKOS FINLAND OYInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Patent number: 9234169Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: July 16, 2009Date of Patent: January 12, 2016Assignee: Glykos FinlandInventors: Johanna Nystedt, Heidi Anderson, Leena Valmu, Jari Natunen, Tero Satomaa
-
Publication number: 20150004143Abstract: The present invention relates to a hematopoietic stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of proteolytic enzymes, such as pronase and pronase-like enzymes in the modification of the cell surface of a hematopoietic stem cell. The present invention further relates to a method of modifying the cell surface of a hematopoietic stem cell by treatment with proteolytic enzymes, such as pronase and pronase-like enzymes.Type: ApplicationFiled: October 4, 2012Publication date: January 1, 2015Inventors: Erja Kerkela, Tanja Hakkarainen, Johanna Nystedt, Jukka Partanen
-
Publication number: 20140248697Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: April 14, 2014Publication date: September 4, 2014Applicant: GLYKOS FINLAND OYInventors: Jarmo LAINE, Taina JAATINEN, Heidi ANDERSON, Johanna NYSTEDT, Sari TIITINEN, Anita LAITINEN, Ulla IMPOLA, Tero Satomaa, Jari NATUNEN, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Patent number: 8546353Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: GrantFiled: May 6, 2011Date of Patent: October 1, 2013Assignee: Glykos Finland OyInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Publication number: 20130034901Abstract: The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme.Type: ApplicationFiled: April 6, 2011Publication date: February 7, 2013Applicant: SUOMEN PUNAINEN RISTI VERIPALVELUInventors: Johanna Nystedt, Tanja Hakkarainen, Petri Lehenkari, Erja Kerkelä, Leena Valmu
-
Publication number: 20120202701Abstract: Antibody-saccharide-complexes and methods and uses related to analysis of cells. Also disclosed is a method of selection of new antibody with CHO-specificity and to a use of antibodies produced for the analysis of stem cells or cancer cells or other cells or tissues known to bind to CHO-antibodies.Type: ApplicationFiled: April 23, 2010Publication date: August 9, 2012Applicants: GLYKOS FINLAND OY, SUOMEN PUNAINEN RISTI, VERIPALVELUInventors: Suvi Natunen, Johanna Nystedt, Heidi Anderson, Jari Natunen
-
Publication number: 20120190058Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: January 17, 2012Publication date: July 26, 2012Applicants: Glykos Finland Oy, SUOMEN PUNAINEN RISTI, VERIPALVELUInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Patent number: 8110366Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: GrantFiled: July 7, 2006Date of Patent: February 7, 2012Assignees: Suomen Punainen Risti, Veripalvelu, Glykos Finland OyInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sarl Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen
-
Publication number: 20110274646Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: ApplicationFiled: May 6, 2011Publication date: November 10, 2011Applicants: Glykos Finland Oy, Suomen Punainen Risti VeripalveluInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Publication number: 20110143373Abstract: The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.Type: ApplicationFiled: July 16, 2009Publication date: June 16, 2011Applicants: SUOMEN PUNAINEN RISTI, VERIPALVELU, GLYKOS FINLAND LTDInventors: Tia Hirvonen, Annika Kotovuori, Virve Pitkanen, Suvi Natunen, Johanna Nystedt, Sari Tiitinen, Leena Valmu, Jari Natunen
-
Publication number: 20110136203Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: July 16, 2009Publication date: June 9, 2011Applicants: SUOMEN PUNAINEN RISTI, VERIPALVELU, GLYKOS FINLAND LTDInventors: Johanna Nystedt, Heidi Anderson, Leena Valmu, Jari Natunen, Tero Satomaa
-
Publication number: 20100047892Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by changing sialylation and/or fucosylation levels of the cells. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. The control methods are preferably mass spectrometric methods.Type: ApplicationFiled: January 18, 2008Publication date: February 25, 2010Applicants: SUOMEN PUNAINEN RISTI,VERIPALVELU, Glykos Finland Ltd.Inventors: Jarmo Laine, Tero Satomaa, Jari Natunen, Taina Jaatinen, Annamari Heiskanen, Johanna Nystedt
-
Publication number: 20090148839Abstract: The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.Type: ApplicationFiled: July 7, 2006Publication date: June 11, 2009Applicants: Suomen Punainen risit Veripalvelu, Glykos Finland OyInventors: Jarmo Laine, Taina Jaatinen, Heidi Anderson, Johanna Nystedt, Sari Tiitinen, Anita Laitinen, Ulla Impola, Tero Satomaa, Jari Natunen, Annamari Heiskanen, Maria Blomqvist, Anne Olonen